PathoFinder Obtains CE Mark for Two Multiplex SARS-CoV-2 MDx Tests

Nov 19, 2020

|

NEW YORK – Dutch molecular diagnostics developer PathoFinder has received CE IVD marking for two multiplex PCR tests for SARS-CoV-2 and other respiratory pathogens.

Specifically, the Maastricht-based firm obtained CE marking for the RespiFinder 2Smart kit for SARS-CoV-2 and Middle East respiratory syndrome-related coronavirus (MERS-CoV) testing, as well as for the RealAccurate Quadriplex (RAQ) Flu/COVID-19 PCR kit.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

PathoFinder Obtains CE Mark for Two Multiplex SARS-CoV-2 MDx Tests

To read the full story....

Breaking News

Somalogic Closes $121M Series A Funding

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

Kantaro Biosciences Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

In Brief This Week: Quest Diagnostics, Fluidigm, BD, and More

Tempus Gets CE Mark for xT Tumor Sequencing Assay

BTIG Downgrades Fulgent Genetics from Buy to Neutral

Featured White Papers

What's Popular?

FDA Issues EUAs for Gravity Diagnostics Coronavirus Test, Sample Self-Collection Kit from RapidRona

BTIG Downgrades Fulgent Genetics from Buy to Neutral

Cepheid Receives CE Mark for SARS-CoV-2, Flu A/B, RSV Combination Test

Startup Angstrom Bio Plans Saliva-Based COVID-19 Nucleic Acid Test on Nanopore Sequencing Platform

AMP Panelists Highlight Need for Careful Lab Stewardship of Infectious Disease MDx

Sponsorships